HIGHLIGHTS
- What: In developing a drug for AD, the major focus should be to prevent the pathogenic processes in the brain leading to cognitive impairment and dementia by giving it at the earliest signs of memory loss, amnestic MCI.
- Who: Marta Weinstock from the Sapienza University of Rome, Italy have published the research work: Therapeutic agents for Alzheimer’s disease: a critical appraisal, in the Journal: (JOURNAL)
SUMMARY
Verubecestat, atabaques and lanabecestat (all worsened cognitive function in subjects with mild- moderate AD) (Egan et_al, 2018; Novak et_al, 2020; Wessels et_al, 2020). The . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.